Product Information
CL594-66170 targets RCAS1 in applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag2905 Product name: Recombinant human EBAG9 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-213 aa of BC017729 Sequence: MAITQFRLFKFCTCLATVFSFLKRLICRSGRGRKLSGDQITLPTTVDYSSVPKQTDVEEWTSWDEDAPTSVKIEGGNGNVATQQNSLEQLEPDYFKDMTPTIRKTQKIVIKKREPLNFGIPDGSTGFSSRLAATQDLPFIHQSSELGDLDTWQENTNAWEEEEDAAWQAEEVLRQQKLADREKRAAEQQRKKMEKEAQRLMKKEQNKIGVKLS Predict reactive species |
| Full Name | estrogen receptor binding site associated, antigen, 9 |
| Calculated Molecular Weight | 213 aa, 24 kDa |
| Observed Molecular Weight | 34 kDa |
| GenBank Accession Number | BC017729 |
| Gene Symbol | RCAS1 |
| Gene ID (NCBI) | 9166 |
| RRID | AB_3084702 |
| Conjugate | CoraLite®594 Fluorescent Dye |
| Excitation/Emission Maxima Wavelengths | 588 nm / 604 nm |
| Form | Liquid |
| Purification Method | Protein G purification |
| UNIPROT ID | O00559 |
| Storage Buffer | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) gene was identified as an estrogen-responsive gene. The gene product, receptor-binding cancer antigen expressed on SiSo cells (RCAS1), is associated with aggressive characteristics and poor overall survival for 15 different human malignancies. The correlation between RCAS1 expression and several clinicopathological variables, including tumor size, clinical stage, invasion depth and lymph node metastasis highlights this molecule's clinical significance. Expression of RCAS1 in tumor cells plays an important role in evasion from host immune system resulting tumor progression, invasion and metastasis. Further exploration of RCAS1 biological function will facilitate development of novel therapeutic strategies that target RCAS1.
